Table 3.
Univariable and multivariable analysis
| Variable | OS | DSS | ||
|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | |
| Univariable | ||||
| Age, years | ||||
| ≤ 60 | 0.73 (0.32–1.66) | 0.46 | 1.04 (0.39–2.80) | 0.93 |
| > 60– ≤ 70 | 1.10 (0.49–2.44) | 0.82 | 0.97 (0.35–2.66) | 0.95 |
| > 70 | 1.37 (0.55–3.43) | 0.5 | 0.99 (0.28–3.46) | 0.98 |
| Gender | ||||
| Male | 0.79 (0.27–2.32) | 0.67 | 0.73 (0.21–2.56) | 0.63 |
| Tumor localization, yes (vs no) | ||||
| Oral cavity | 2.34 (0.65–7.69) | 0.2 | 3.11 (0.87–11.13) | 0.08 |
| Oropharynx | 0.59 (0.25–1.42) | 0.24 | 0.68 (0.24–1.96) | 0.47 |
| Hypopharynx | 0.93 (0.38–2.24) | 0.86 | 0.89 (0.27–2.76) | 0.84 |
| Larynx | 0.92 (0.35–2.46) | 0.87 | 0.52 (0.12–2.78) | 0.38 |
| Multicompartmental | 3.56 (1.05–12.02) | 0.004* | 3.47 (0.79–15.33) | 0.1 |
| T and N classification, yes (vs no) | ||||
| c/pT3–4 | 0.86 (0.38–1.95) | 0.72 | 0.65 (0.24–1.74) | 0.39 |
| c/pN2b–3 | 1.12 (0.47–2.67) | 0.81 | 1.92 (0.55–6.74) | 0.31 |
| AJCC stage IV | 1.85 (0.55–6.18) | 0.32 | 1.83 (0.42–8.10) | 0.42 |
| Concomitant systemic therapy, yes (vs no) | ||||
| Any | 0.48 (0.16–1.42) | 0.22 | 0.32 (0.10–1.01) | 0.08 |
| Platin–based | 0.62 (0.27–1.41) | 0.26 | 0.62 (0.22–1.71) | 0.37 |
| Cetuximab | 1.19 (0.44–3.17) | 0.74 | 0.68 (0.16–3.01) | 0.60 |
| NLR (IQR, 2.1–4.7) | ||||
| > Median (= 3.5) | 2.27 (1.00–5.14) | 0.05 | 2.12 (0.77–5.85) | 0.15 |
| > 2.1 | 1.41 (0.53–3.77) | 0.49 | 0.76 (0.26–2.18) | 0.61 |
| > 4.7 | 3.44 (1.55–7.62) | 0.002* | 3.30 (1.22–8.93) | 0.018* |
| PLR (IQR, 133–249) | ||||
| > Median (= 195) | 2.63 (1.13–6.12) | 0.0246* | 2.71 (0.94–7.82) | 0.06 |
| > 133 | 5.12 (1.20–21.7) | 0.027* | 6.53 (0.86–49.5) | 0.07 |
| > 249 | 2.48 (1.09–5.66) | 0.0307* | 3.25 (1.20–8.76) | 0.0201* |
| SUVmax (IQR, 10.2–18.6) | ||||
| > Median (= 15.7) | 0.92 (0.42–2.02) | 0.84 | 1.32 (0.49–3.53) | 0.59 |
| > 10.2 | 1.84 (0.63–4.5.38) | 0.26 | 1.54 (0.44–5.40) | 0.50 |
| > 18.6 | 1.32 (0.55–3.18) | 0.53 | 1.09 (0.35–3.37) | 0.89 |
| MTV (IQR, 3.7–11.2) | ||||
| > Median (= 6.5) | 1.98 (0.89–4.12) | 0.1 | 2.22 (0.80–6.11) | 0.12 |
| > 3.7 | 2.55 (0.76–8.57) | 0.13 | 2.61 (0.59–11.5) | 0.21 |
| > 11.2 | 1.31 (0.55–3.14) | 0.55 | 1.54 (0.54–4.44) | 0.42 |
| TLG (IQR, 32–109) | ||||
| > Median (= 54) | 1.90 (0.54–2.61) | 0.67 | 1.47 (0.55–3.96) | 0.44 |
| > 32 | 4.97 (1.17–21.1) | 0.029* | 6.76 (0.89–51.2) | 0.06 |
| > 109 | 1.76 (0.76–4.10) | 0.19 | 1.71 (0.59–4.91) | 0.32 |
| Multivariable | ||||
| Model NLR | ||||
| Multicompartmental | 5.05 (1.43–17.8) | 0.0118* | – | – |
| NLR > 4.7 | 3.94 (1.73–8.97) | 0.0011* | – | – |
| Model PLR | ||||
| Multicompartmental | 7.10 (1.82–27.7) | 0.0048* | – | – |
| PLR > median (= 195) | 3.59 (1.40–9.20) | 0.0078* | – | – |
| Model TLG | ||||
| Multicompartmental | 3.93 (1.16–13.3) | 0.0279* | – | – |
| TLG > 32 | 5.18 (1.22–22.0) | 0.026* | – | – |
NLR Neutrophil-to-lymphocyte ratio, PLR platelet-to-lymphocyte ratio, MTV metabolic tumor volume, * = statistically significant